Results 21 to 30 of about 1,650 (186)

Spectrophotometric determination of quetiapine fumarate in pharmaceuticals and human urine by two charge-transfer complexation reactions [PDF]

Chemical Industry and Chemical Engineering Quarterly, 2012
Two simple, rapid and accurate spectrophotometric procedures are proposed for the determination of quetiapine fumarate (QTF) in pharmaceuticals and in spiked human urine.
Vinay K.B., Revenasiddappa H.D.
doaj   +3 more sources

QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential

Bulletin of Faculty of Pharmacy Cairo University, 2018
The present work aims to discuss on Quality by Design based development and characterization of the sustained release mucoadhesive microspheres of quetiapine fumarate. The microspheres were prepared by non-aqueous solvent evaporation process.
Someshwar Komati, Suryakanta Swain, Muddana Eswara Bhanoji Rao, Bikash Ranjan Jena, Sambamoorthy Unnam, Vishali Dasi   +5 more
doaj   +2 more sources

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder

Neuropsychiatric Disease and Treatment, 2012
Jean Endicott,1 Henrik Svedsäter,2 Julie C Locklear21Department of Psychiatry, Columbia University, New York, NY; 2AstraZeneca Pharmaceuticals, Wilmington, DE, USABackground: We evaluated the effects of once-daily extended-release quetiapine ...
Endicott J, Svedsäter H, Locklear JC   +2 more
doaj   +1 more source

Formulation Design and Optimization of Orodispersible Tablets of Quetiapine Fumarate by Sublimation Method. [PDF]

Indian J Pharm Sci, 2015
The objective of present study was to formulate directly compressible orodispersible tablets of quetiapine fumarate by sublimation method with a view to enhance patient compliance. A full 3(2) factorial design was used to investigate the effect of two variables viz., concentration of Indion 414 and camphor.
Kalyankar P, Panzade P, Lahoti S.
europepmc   +4 more sources

Comparative efficacy of lithium carbonate loading dose versus standard dosing, each combined with quetiapine, in acute mania of bipolar I disorder: a randomized single-blind controlled trial [PDF]

BMC Psychiatry
Introduction Bipolar disorder type I is defined by the occurrence of at least one manic episode, presenting with elevated mood, hyperactivity, and restlessness.
Ebrahim Moghimi-Sarani, Seyedeh Zahra Etemad, Raziye Dehbozorgi   +2 more
doaj   +2 more sources

Development and validation of simple HPTLC – UV assay method for determination of quetiapine fumarate concentrations in simulated plasma fluid

Journal of Applied Pharmaceutical Research
Background: Quetiapine fumarate (QTF) is a high-affinity monoaminergic antagonist selective for serotonin Type 2 (5HT2) and dopamine Type 2 (D2) receptors.
Aakanksha Sinha, S J Daharwal
doaj   +3 more sources

Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study [PDF]

BMC Psychiatry, 2012
Background Comorbid anxiety symptoms,in patients with a primary anxiety disorder or a mood disorder, leads to poor patient outcomes and burdens the healthcare system.
Chen Yi-Chih, Chen Chih-Ken, Wang Liang-Jen   +2 more
doaj   +2 more sources

Quetiapine Fumarate Extended-release Tablet Formulation Design Using Artificial Neural Networks. [PDF]

Turk J Pharm Sci, 2017
Objectives: This design study was implemented within the scope of the quality by design approach, which included the "International Conference on Harmonization" guidelines.
Özçelik E, Mesut B, Aksu B, Özsoy Y.
europepmc   +2 more sources

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial

Health Technology Assessment
Background Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly, and none for longer than 8 weeks.
Jess Kerr-Gaffney, Zohra Zenasni, Kimberley Goldsmith, Nahel Yaziji, Huajie Jin, Alessandro Colasanti, John Geddes, David Kessler, R Hamish McAllister-Williams, Allan H Young, Alvaro Barrera, Lindsey Marwood, Rachael W Taylor, Helena Tee, Anthony J Cleare   +14 more
doaj   +2 more sources

Coma After Quetiapine Fumarate Intentional Overdose in a 71-year-old Man: A Case Report. [PDF]

Drug Saf Case Rep, 2015
A 71-year-old man developed coma with severe respiratory failure, hypotension, and tachycardia induced by the intentional ingestion of quetiapine fumarate extended release (XR) 20 g.
Gibiino S, Trappoli A, Balzarro B, Atti AR, De Ronchi D.   +4 more
europepmc   +2 more sources